Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
Transducer Mechanism: Nuclear Receptors01:31

Transducer Mechanism: Nuclear Receptors

2.4K
Nuclear receptors, or NRs, are unique transcription factors that regulate gene transcription and affect the cellular pathways involved in reproduction, development, or metabolism. Their ability to be stimulated by small lipophilic ligands and control vital cellular processes makes them ideal drug targets. Nearly 10-15% of currently prescribed drugs target these receptors.
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
2.4K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

4.6K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.6K
Experimental RNAi02:15

Experimental RNAi

7.3K
RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
7.3K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

PEPN1924, A Phase II Study of Trastuzumab Deruxtecan in Patients With Recurrent Human Epidermal Growth Factor Receptor 2+ Osteosarcoma: A Children's Oncology Group Pediatric Early-Phase Clinical Trial Network Study.

JCO oncology advances·2026
Same author

Nous-209 neoantigen vaccine for cancer prevention in Lynch syndrome carriers: a phase 1b/2 trial.

Nature medicine·2026
Same author

Yes, It Is Worth It: Consider Participant Experiences in the Design of Future Trials.

Cancer prevention research (Philadelphia, Pa.)·2026
Same author

Repurposing of the Macrolide Antibiotic Clarithromycin for the Prevention of Lung Cancer.

Molecular cancer therapeutics·2025
Same author

Integrated single cell spatial multi-omics landscape of WHO grades 2-4 diffuse gliomas identifies locoregional metabolomic regulators of glioma growth.

bioRxiv : the preprint server for biology·2025
Same author

Development of an H&E on-block staining technique for collagen detection in cryo-fluorescence tomography imaging of frozen breast tissue samples.

medRxiv : the preprint server for health sciences·2025

相关实验视频

Updated: Jan 14, 2026

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
09:29

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model

Published on: March 20, 2020

18.8K

针对RXR途径预防三阴性乳腺癌.

Cassandra L Moyer1, Jamal L Hill1, Darian Coleman2

  • 1The University of Texas MD Anderson Cancer Center, Houston, TX, United States.

Cancer prevention research (Philadelphia, Pa.)
|October 24, 2025
PubMed
概括

核视网体X受体 (RXR) 激动剂在预防三阴性乳腺癌 (TNBCs) 方面表现有前途. 临床前研究表明,RXR激动剂在ER阴性模型中显著延迟瘤形成,为预防乳腺癌提供了潜在的新途径.

更多相关视频

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment
11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

2.3K
Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells
07:23

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells

Published on: May 30, 2025

1.1K

相关实验视频

Last Updated: Jan 14, 2026

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
09:29

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model

Published on: March 20, 2020

18.8K
Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment
11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

2.3K
Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells
07:23

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells

Published on: May 30, 2025

1.1K

科学领域:

  • 在瘤学瘤学.
  • 分子生物学分子生物学
  • 药理学 药理学是指药理学的学科.

背景情况:

  • 选择性雌激素受体调节剂 (SERM) 和芳香酶抑制剂 (AI) 预防ER阳性乳腺癌,但不能预防ER阴性或三阴性乳腺癌 (TNBCs).
  • 核雌激素受体 (ER) 途径是预防乳腺癌的关键目标.

研究的目的:

  • 评估核视网体X受体 (RXR) 激动剂,IRX4204和9cUAB30在预防ER阴性和三阴性乳腺癌 (TNBC) 发展方面的疗效.
  • 探索超越ER向治疗的新型治疗策略,用于TNBC预防.

主要方法:

  • 在三个ER阴性小鼠模型中测试RXR激动剂IRX4204和9cUAB30:MMTV-ErbB2,C3(1) / SV40-TAg,以及Brca1缺乏.
  • 评估治疗与载体控制组中的瘤形成延迟,发病率和存活率.
  • 生物标志物分析,包括Ki-67表达和细胞毒性T细胞透.

主要成果:

  • 在所有三个ER阴性小鼠模型中,IRX4204显著延迟了乳腺瘤的形成,毒性适度.
  • 在一些用IRX4204.4治疗的MMTV-ErbB2小鼠中观察到乳腺瘤的完全预防.
  • 在延迟瘤中,IRX4204治疗导致Ki-67表达减少和细胞毒性T细胞透增加.
  • 9cUAB30在brca1缺乏的小鼠中也延迟了瘤的形成,但比IRX4204.4的程度要小.

结论:

  • RXR激抗剂,特别是IRX4204,在预防ER阴性和三阴性乳腺癌发育方面表现出显著的临床前疗效.
  • 这些发现支持进一步研究RXR激抗剂作为TNBC的预防策略.
  • 瘤细胞增殖 (Ki-67) 和免疫反应 (T细胞) 的调节是RXR主动剂疗效的潜在机制.